Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922542 · ClinicalTrials.gov registry record · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
A Phase 2 study of Keratoconus and Ectasia Corneal, sponsored by Price Vision Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
- 1
- Study location
NCT03922542: Recruiting Phase 2 study of Keratoconus and Ectasia Corneal, sponsored by Price Vision Group.
NCT03922542 is a Phase 2 study of Keratoconus and Ectasia Corneal that is actively recruiting participants, run by Price Vision Group. The registered enrollment target is 510 participants, below the 1,156-participant average among 21 other Keratoconus trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03922542, a Phase 2 study of Keratoconus and Ectasia Corneal, is actively recruiting participants, sponsored by Price Vision Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
Primary Outcome
assessed by corneal tomography
Conditions Studied
Interventions
- COMBINATION_PRODUCT riboflavin 0.1%
- COMBINATION_PRODUCT Riboflavin 0.1%
Study Locations (1)
Indiana
- Price Vision Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
What NCT03922542 shows while recruiting
NCT03922542 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, below the 1,156-participant average among 21 other Keratoconus trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Keratoconus appearing as the primary indexed condition, and to 2 interventions - of which riboflavin 0.1% is the first listed.
NCT03922542 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03922542 about?
NCT03922542 is a clinical study titled "Comparison of Standard vs. Accelerated Corneal Crosslinking". The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
What is the current status of trial NCT03922542?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2019-04-16. Estimated completion is 2026-07-01.
What conditions does trial NCT03922542 study?
This clinical trial studies the following conditions: Keratoconus, Ectasia Corneal.
What interventions are being tested in trial NCT03922542?
The interventions under investigation include: riboflavin 0.1% (COMBINATION_PRODUCT), Riboflavin 0.1% (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03922542?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922542 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03922542's enrollment target sits among peer trials
510 2nd of 21 the highest of 21 other Keratoconus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keratoconus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
-
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
RECRUITING · Phase 2
-
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
RECRUITING · Phase 2
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
- NCT05561387 · 510 participants · Phase 3
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI